Landos Biopharma (LABP)
(Delayed Data from NSDQ)
$22.24 USD
-0.02 (-0.07%)
Updated May 3, 2024 03:59 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Cash flow Statements
Fiscal Year End for Landos Biopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -21.94 | -39.28 | -38.42 | -30.14 | -13.47 |
Depreciation/Amortization & Depletion | 0.04 | 1.73 | 0.20 | 0.35 | 0.10 |
Net Change from Assets/Liabilities | 0.44 | -10.07 | 5.89 | 5.87 | 3.28 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.97 | 1.85 | 5.27 | 0.96 | 0.21 |
Net Cash From Operating Activities | -20.48 | -45.77 | -27.06 | -22.96 | -9.87 |
Property & Equipment | 0.00 | 0.23 | -0.44 | -0.18 | -0.16 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 7.78 | 73.83 | -58.27 | 14.31 | -40.17 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 7.78 | 74.06 | -58.71 | 14.13 | -40.33 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 13.57 | 0.00 | 93.51 | 1.52 | 51.67 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 7.98 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -1.91 | 0.00 | 0.00 |
Net Cash from Financing Activities | 13.57 | 0.00 | 91.61 | 1.52 | 59.65 |
Effect of Exchange Rate Changes | 0.04 | 0.05 | 0.05 | -0.08 | 0.00 |
Net Change In Cash & Equivalents | 0.91 | 28.34 | 5.89 | -7.39 | 9.45 |
Cash at Beginning of Period | 36.64 | 8.31 | 2.42 | 9.81 | 0.36 |
Cash at End of Period | 37.55 | 36.64 | 8.31 | 2.42 | 9.81 |
Diluted Net EPS | -3.50 | -9.80 | -10.20 | -24.70 | NA |
Fiscal Year End for Landos Biopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -21.94 | -15.82 | -9.96 | -6.03 |
Depreciation/Amortization & Depletion | NA | 0.04 | 0.04 | 0.05 | 0.03 |
Net Change from Assets/Liabilities | NA | 0.44 | -0.46 | -3.85 | -2.39 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 0.97 | 0.73 | 0.48 | 0.22 |
Net Cash From Operating Activities | NA | -20.48 | -15.51 | -13.28 | -8.17 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 7.78 | 7.71 | 7.08 | 3.10 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 7.78 | 7.71 | 7.08 | 3.10 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 13.57 | 13.57 | 13.57 | 13.67 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 13.57 | 13.57 | 13.57 | 13.67 |
Effect of Exchange Rate Changes | NA | 0.04 | 0.05 | 0.04 | 0.00 |
Net Change In Cash & Equivalents | NA | 0.91 | 5.82 | 7.41 | 8.60 |
Cash at Beginning of Period | NA | 36.64 | 36.64 | 36.64 | 36.64 |
Cash at End of Period | NA | 37.55 | 42.46 | 44.05 | 45.24 |
Diluted Net EPS | NA | -1.03 | -0.94 | -0.63 | -0.90 |